Goldman Sachs lowered the firm’s price target on Novo Nordisk (NVO) to $54 from $60 and keeps a Buy rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- As America’s Job Market Cracks, Here Are the Layoff Announcements You Can’t Ignore
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Midday Fly By: Dell, HP move in opposite directions after earnings
- Trump Trade: Trump says ‘tremendous progress’ on ending Ukrainian war
- Novo Nordisk Stock (NVO) Jumps after Ozempic and Wegovy Prices Cut 71% under Medicare Plan